Aytu Biopharma (AYTU) Income from Continuing Operations (2010 - 2026)
Aytu Biopharma's (AYTU) quarterly Income from Continuing Operations came in at 5618000.0 in Q1 2026, down 243.39% year-on-year from 3918000.0 in Q1 2025, and up 46.92% on a QoQ basis from 10584000.0 in Q4 2025.
Aytu Biopharma (AYTU) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has 17 years of Income from Continuing Operations data on file, last reported at 5618000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 243.39% year-over-year to 5618000.0 in Q1 2026; TTM through Mar 2026 was 33706000.0, a 1420.25% decrease from a year earlier, with the FY2025 full-year figure at 13771000.0, down 12.29% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 5618000.0, up from 10584000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for AYTU reached as high as 6960000.0 in Q2 2022 and fell as low as 53291000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 6099823.53 across 5 years, with a median of 2457000.0 in 2023.
- On a YoY basis, Income from Continuing Operations climbed as much as 271.24% in 2025 and fell as far as 1691.58% in 2025.
- Year by year, Income from Continuing Operations stood at 6693000.0 in 2022, then surged by 108.95% to 599000.0 in 2023, then climbed by 11.02% to 665000.0 in 2024, then slumped by 1691.58% to 10584000.0 in 2025, then soared by 46.92% to 5618000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 5618000.0 in Q1 2026, 10584000.0 in Q4 2025, and 1965000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Aytu Biopharma | 1.43 Mn | -25.28 Mn | 7.60 Mn | -5.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.62 Mn |
| Dec 31, 2025 | -10.58 Mn |
| Sep 30, 2025 | 1.97 Mn |
| Jun 30, 2025 | -19.47 Mn |
| Mar 31, 2025 | 3.92 Mn |
| Dec 31, 2024 | 665,000.00 |
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | -3.12 Mn |
| Mar 31, 2024 | -2.29 Mn |
| Dec 31, 2023 | 599,000.00 |
| Sep 30, 2023 | -7.47 Mn |
| Jun 30, 2023 | -2.46 Mn |
| Mar 31, 2023 | -7.20 Mn |
| Dec 31, 2022 | -6.69 Mn |
| Sep 30, 2022 | -701,000.00 |
| Jun 30, 2022 | 6.96 Mn |
| Mar 31, 2022 | -53.29 Mn |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -27.85 Mn |
| Jun 30, 2021 | -18.74 Mn |